Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOVER-WaM phase 2 study of CLR131 in relapsed or refractory Waldenstrom macroglobulinemia
MOH_2021-10-04_010283Phase 2Recruiting
- Sponsor
- Cellectar Biosciences
- Start
- Aug 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iopofosine I-131 in Waldenström macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL), sponsored by Cellectar Biosciences. Primary endpoint: Major response rate. Started Aug 2021; status: recruiting.
02
Drugs
Iopofosine I-131
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on MOH_2021-10-04_010283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-04_010283.